Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice

Carcinogenesis

Volumn 33, Issue 2, 2012, Pages 326-330

  Bi, Xiuli ^a,b   Pohl, Nicole M ^b   Qian, Zhibin ^c   Yang, George R ^b   Gou, Yuan ^b   Guzman, Grace ^b   Kajdacsy Balla, Andre ^b   Iozzo, Renato V ^d   Yang, Wancai ^b,c  

^a LIAONING UNIVERSITY   (China)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c XINXIANG MEDICAL UNIVERSITY   (China)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECORIN; MESSENGER RNA; PLASMID VECTOR; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; KNOCKOUT MOUSE; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN CONTENT; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UPREGULATION;

EID: 84863012228     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr293     Document Type: Article

References (44)

1. Iozzo, R.V. et al. (2010) Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J., 277, 3864-3875.
2. Goldoni, S. et al. (2008) Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int. J. Cancer, 123, 2473-2479.
3. Bi, X. et al. (2008) Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis, 29, 1435-1440.
4. Santra, M. et al. (1995) De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci U S A, 92, 7016-7020.
5. Stander, M. et al. (1999) Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res., 296, 221-227.
6. De Luca, A. et al. (1996) Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J. Biol. Chem., 271, 18961-18965.
7. Banerjee, A.G. et al. (2003) Aberrant expression and localization of decorin in human oral dysplasia and squamous cell carcinoma. Cancer Res., 63, 7769-7776.
8. Asakura, S. et al. (1999) Role of transforming growth factor-beta1 and decorin in development of central fibrosis in pulmonary adenocarcinoma. Hum. Pathol., 30, 195-198.
9. Iozzo, R.V. et al. (1999) Decorin is a biological ligand for the epidermal growth factor receptor. J. Biol. Chem., 274, 4489-4492.
10. Csordas, G. et al. (2000) Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J. Biol. Chem., 275, 32879-32887.
11. Reed, C.C. et al. (2002) Suppression of tumorigenicity by adenovirusmediated gene transfer of decorin. Oncogene, 21, 3688-3695.
12. Iozzo, R.V. et al. (1999) Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc. Natl Acad. Sci. U S A, 96, 3092-3097.
13. Troup, S. et al. (2003) Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in nodenegative invasive breast cancer. Clin. Cancer Res., 9, 207-214.
14. Campioni, M. et al. (2008) Identification of genes down-regulated during lung cancer progression: a cDNA array study. J. Exp. Clin. Cancer Res., 27, 38.
15. Goldoni, S. et al. (2008) An antimetastatic role for decorin in breast cancer. Am. J. Pathol., 173, 844-855.
16. Reed, C.C. et al. (2005) Decorin prevents metastatic spreading of breast cancer. Oncogene, 24, 1104-1110.
17. Danielson, K.G. et al. (1997) Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J. Cell Biol., 136, 729-743.
18. Goldoni, S. et al. (2009) Decorin is a novel antagonistic ligand of the Met receptor. J. Cell Biol., 185, 743-754.
19. Schmalhofer, O. et al. (2009) E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev., 28,151-166.
20. Nelson, W.J. et al. (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science, 303, 1483-1487.
21. Rosenberg, S.A. et al. (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science, 233, 1318-1321.
22. Bi, X. et al. (2010) Black Raspberries inhibit intestinal tumorigenesis in Apc1638+/-and Muc2-/- mouse models of colorectal cancer. Cancer Prev. Res. (Phila), 3, 1443-1450.
23. Horiguchi, K. et al. (2009) Role of Ras signaling in the induction of snail by transforming growth factor-beta. J. Biol. Chem., 284, 245-253.
24. Fang, W. et al. (2010) Functional and physical interaction between the selenium-binding protein 1 (SBP1) and the glutathione peroxidase 1 selenoprotein. Carcinogenesis, 31, 1360-1366.
25. Kelloff, G.J. et al. (2006) Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin. Cancer Res., 12, 3661-3697.
26. Wheelock, M.J. et al. (2003) Cadherins as modulators of cellular phenotype. Annu. Rev. Cell Dev. Biol., 19, 207-235.
27. Doki, Y. et al. (1993) Correlation between E-cadherin expression and invasiveness in vitro in a human esophageal cancer cell line. Cancer Res., 53, 3421-3426.
28. Oka, H. et al. (1993) Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res., 53, 1696-1701.
29. Umbas, R. et al. (1994) Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res., 54, 3929-3933.
30. Derksen, P.W. et al. (2006) Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell, 10, 437-449.
31. Frixen, U.H. et al. (1991) E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol., 113, 173-185.
32. Onder, T.T. et al. (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res., 68, 3645-3654.
33. Baranwal, S. et al. (2009) Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem. Biophys. Res. Commun., 384, 6-11.
34. Yang, C.C. et al. (2009) Inflamed snail speeds metastasis. Cancer Cell, 15, 355-357.
35. Yang, J. et al. (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell, 14, 818-829.
36. Logan, C.Y. et al. (2004) The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol., 20, 781-810.
37. van de Wetering, M. et al. (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell, 111, 241-250.
38. Fujita, Y. et al. (2002) Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat. Cell Biol., 4, 222-231.
39. Pece, S. et al. (2002) E-cadherin and Hakai: signalling, remodeling or destruction? Nat. Cell Biol., 4, E72-E74.
40. Saitoh, M. et al. (2009) Regulation of the stability of cell surface E-cadherin by the proteasome. Biochem. Biophys. Res. Commun., 381, 560-565.
41. Theard, D. et al. (2008) Formation of E-cadherin/beta-catenin-based adherens junctions in hepatocytes requires serine-10 in p27(Kip1). Mol. Biol. Cell, 19, 1605-1613.
42. Mueller, S. et al. (2000) p21WAF1 regulates anchorage-independent growth of HCT116 colon carcinoma cells via E-cadherin expression. Cancer Res., 60, 156-163.
43. Fedor-Chaiken, M. et al. (2003) E-cadherin binding modulates EGF receptor activation. Cell Commun. Adhes., 10, 105-118.
44. Lu, Z. et al. (2003) Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell, 4, 499-515.